NASDAQ$LYEL

Lyell Immunopharma Inc · Q2 2025 earnings

Q2 2025 earnings · · After market close · Investor relations

Reports in 5 weeks

Lyell Immunopharma hasn't published Q2 2025 actuals yet. The tiles below frame what to compare against; sections further down are historical context only.

  • Most recent report

    Q1 2026

    Revenue
    $2K
    EPS
    -$1.10
  • Year-ago · Q2 2024

    Q2 2024

    Revenue
    $13K
    EPS
    -$0.18
  • FY2025 consensus

    Analyst consensus

    Revenue
    $43.3K
    EPS
    -$0.65

Revenue & EPS history

Lyell Immunopharma · Revenue · Quarterly

$2K

Q1 2026+28,471.4%vs Q1 2025

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports

Historical avg

+1.5%

Avg return

Earnings day

-4.0%

Avg return

5 days after

+1.1%

Avg return

30 days after

73%

16 / 22 earnings

Positive

+20.3%

Q4 2024

Best reaction

-18.3%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.1%-7.0%-42.1%
Q4 2025+2.5%-19.0%-9.6%
Q3 2025-1.3%+1.7%+95.5%
Q1 2025+4.6%+2.0%+21.1%
Q4 2024+20.3%+15.5%-10.3%
Q3 2024-17.6%-21.3%-38.9%
Q2 2024+1.4%-8.1%-20.9%
Q1 2024+7.6%+4.2%+13.6%
Q4 2023+2.5%-8.6%-21.8%
Q3 2023+6.8%-24.8%-11.8%
Q2 2023+1.5%-1.9%-16.8%
Q1 2023+6.9%+6.5%+50.9%
Q4 2022+9.6%+1.4%-1.8%
Q3 2022-18.3%-17.0%-28.8%
Q2 2022+16.3%+20.2%+10.1%
Q1 2021-12.4%-22.8%+1.5%
Q1 2022-12.4%-22.8%+1.5%
Q4 2019+6.1%+6.1%+1.6%
Q4 2021+6.1%+6.1%+1.6%
Q3 2021-4.1%-3.6%-18.8%
Q4 2020+2.8%+2.2%+24.6%
Q2 2021+2.8%+2.2%+24.6%
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro